Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)
677 patients were included in the study and randomly assigned to either methylprednisolone 80 mg as a continuous daily infusion for 8 days followed by slow tapering or dexamethasone 6 mg daily for up to 10 days in adult patients with COVID-19 pneumonia requiring oxygen or noninvasive respiratory support
There was no significant difference in mortality between the two groups by day 28
Methylprednisolone did not reduce mortality at 28 days compared to conventional dexamethasone in COVID-19 pneumonia